January 28, 2025
.webp)
The maternal health crisis in the United States is alarming, demanding innovation, determination, and a commitment to equitable care solutions. Delfina has stepped up to this challenge with its mission to transform maternal health outcomes with AI-powered care. Today, we proudly announce our $17 million Series A, led by US Venture Partners (USVP). This milestone represents a pivotal moment in our mission to create a safer, healthier future for expecting parents and their babies.
A Critical Approach to Systemic Challenges in Maternal Health
With a maternal mortality rate more than twice as high as other high-income countries, the U.S. faces a worsening crisis. Black women face disproportionately higher risks, with maternal mortality nearly triple the rate of white women and preterm birth rates 1.4 times higher. Addressing these grave disparities requires a focused commitment and actionable solutions that prioritize equitable access to quality care and address unmet social determinants of health.
Delfina’s AI-powered maternal health platform has already had a measurable impact in these areas. By combining cutting-edge predictive analytics, individualized care interventions, and seamless integration with primary prenatal care teams, Delfina is setting the new standard for proactive, virtual, and data-driven maternal healthcare.
Proven Success with Evidence-Based Care
Healthcare providers who have adopted Delfina are seeing the results firsthand. Our partners – and our data – report marked reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes—key drivers of maternal and infant mortality. Based on these improved health outcomes, Delfina guarantees threefold same-year cost savings for health plans. The combination of healthier pregnancies and reduced healthcare costs highlights the value created by Delfina Care.
Dr. Fatimah Lalani, Chief Medical Officer at HOPE Clinic in Houston, Texas, shares how Delfina’s AI-powered interventions have improved maternal health. “Since we transformed our practice with Delfina Care, we have seen the positive impact on our pregnant patients’ care daily. We see many patients whose cardiovascular and metabolic challenges we can now proactively manage thanks to Delfina’s insights. Our clinicians have been empowered by Delfina’s system to efficiently provide a new level of proactive care for healthy pregnancy outcomes.”
A Vision for National Scaling and Innovation
The $17 million raised in Delfina’s Series A round will propel our company into our next chapter of growth and innovation. This funding will accelerate our ability to serve more patients nationwide while enhancing our industry-leading predictive technology and interventional support. With our concerted focus on improving maternal health outcomes for all, including in underserved communities, Delfina will serve as a leading technology partner for payors, providers, and families nationwide.
Dr. Senan Ebrahim, Delfina’s founder and CEO, reflects on this funding milestone and its significance for maternal health equity. “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis,” Dr. Ebrahim emphasizes. “We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
Investor Confidence in Life-Changing Innovation
Our Series A is a testament to investor enthusiasm about Delfina’s unique ability to disrupt maternal healthcare for the better. USVP led the round. Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved,” said Dafina Toncheva, USVP General Partner. “We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.
New investors include ARTIS Ventures, Mayo Clinic, and Tokio Marine Future Fund. Additional support came from our existing investors, including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures. Our robust investor ecosystem reinforces the industry’s confidence in Delfina as a leader in solving the maternal health crisis.
Changing the Future of Maternal Care
With this new investment, we are poised to scale the Delfina Care platform and continue delivering on our promise of safer, healthier pregnancies for all. Our focus on improving healthcare outcomes for underserved and underrepresented communities continues, ensuring that no patient is left behind. This is a landmark moment for Delfina and maternal health as a whole—a step toward equity, innovation, and measurable transformation.
The message is clear. Delfina is reimagining how we approach maternal health through technology-driven interventions, compassionate care, and a commitment to reducing disparities. To learn more about our mission and impact, send us a note at partner@delfina.com.
January 28, 2025
The maternal health crisis in the United States is alarming, demanding innovation, determination, and a commitment to equitable care solutions. Delfina has stepped up to this challenge with its mission to transform maternal health outcomes with AI-powered care. Today, we proudly announce our $17 million Series A, led by US Venture Partners (USVP). This milestone represents a pivotal moment in our mission to create a safer, healthier future for expecting parents and their babies.
A Critical Approach to Systemic Challenges in Maternal Health
With a maternal mortality rate more than twice as high as other high-income countries, the U.S. faces a worsening crisis. Black women face disproportionately higher risks, with maternal mortality nearly triple the rate of white women and preterm birth rates 1.4 times higher. Addressing these grave disparities requires a focused commitment and actionable solutions that prioritize equitable access to quality care and address unmet social determinants of health.
Delfina’s AI-powered maternal health platform has already had a measurable impact in these areas. By combining cutting-edge predictive analytics, individualized care interventions, and seamless integration with primary prenatal care teams, Delfina is setting the new standard for proactive, virtual, and data-driven maternal healthcare.
Proven Success with Evidence-Based Care
Healthcare providers who have adopted Delfina are seeing the results firsthand. Our partners – and our data – report marked reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes—key drivers of maternal and infant mortality. Based on these improved health outcomes, Delfina guarantees threefold same-year cost savings for health plans. The combination of healthier pregnancies and reduced healthcare costs highlights the value created by Delfina Care.
Dr. Fatimah Lalani, Chief Medical Officer at HOPE Clinic in Houston, Texas, shares how Delfina’s AI-powered interventions have improved maternal health. “Since we transformed our practice with Delfina Care, we have seen the positive impact on our pregnant patients’ care daily. We see many patients whose cardiovascular and metabolic challenges we can now proactively manage thanks to Delfina’s insights. Our clinicians have been empowered by Delfina’s system to efficiently provide a new level of proactive care for healthy pregnancy outcomes.”
A Vision for National Scaling and Innovation
The $17 million raised in Delfina’s Series A round will propel our company into our next chapter of growth and innovation. This funding will accelerate our ability to serve more patients nationwide while enhancing our industry-leading predictive technology and interventional support. With our concerted focus on improving maternal health outcomes for all, including in underserved communities, Delfina will serve as a leading technology partner for payors, providers, and families nationwide.
Dr. Senan Ebrahim, Delfina’s founder and CEO, reflects on this funding milestone and its significance for maternal health equity. “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis,” Dr. Ebrahim emphasizes. “We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
Investor Confidence in Life-Changing Innovation
Our Series A is a testament to investor enthusiasm about Delfina’s unique ability to disrupt maternal healthcare for the better. USVP led the round. Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved,” said Dafina Toncheva, USVP General Partner. “We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.
New investors include ARTIS Ventures, Mayo Clinic, and Tokio Marine Future Fund. Additional support came from our existing investors, including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures. Our robust investor ecosystem reinforces the industry’s confidence in Delfina as a leader in solving the maternal health crisis.
Changing the Future of Maternal Care
With this new investment, we are poised to scale the Delfina Care platform and continue delivering on our promise of safer, healthier pregnancies for all. Our focus on improving healthcare outcomes for underserved and underrepresented communities continues, ensuring that no patient is left behind. This is a landmark moment for Delfina and maternal health as a whole—a step toward equity, innovation, and measurable transformation.
The message is clear. Delfina is reimagining how we approach maternal health through technology-driven interventions, compassionate care, and a commitment to reducing disparities. To learn more about our mission and impact, send us a note at partner@delfina.com.
January 28, 2025
The maternal health crisis in the United States is alarming, demanding innovation, determination, and a commitment to equitable care solutions. Delfina has stepped up to this challenge with its mission to transform maternal health outcomes with AI-powered care. Today, we proudly announce our $17 million Series A, led by US Venture Partners (USVP). This milestone represents a pivotal moment in our mission to create a safer, healthier future for expecting parents and their babies.
A Critical Approach to Systemic Challenges in Maternal Health
With a maternal mortality rate more than twice as high as other high-income countries, the U.S. faces a worsening crisis. Black women face disproportionately higher risks, with maternal mortality nearly triple the rate of white women and preterm birth rates 1.4 times higher. Addressing these grave disparities requires a focused commitment and actionable solutions that prioritize equitable access to quality care and address unmet social determinants of health.
Delfina’s AI-powered maternal health platform has already had a measurable impact in these areas. By combining cutting-edge predictive analytics, individualized care interventions, and seamless integration with primary prenatal care teams, Delfina is setting the new standard for proactive, virtual, and data-driven maternal healthcare.
Proven Success with Evidence-Based Care
Healthcare providers who have adopted Delfina are seeing the results firsthand. Our partners – and our data – report marked reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes—key drivers of maternal and infant mortality. Based on these improved health outcomes, Delfina guarantees threefold same-year cost savings for health plans. The combination of healthier pregnancies and reduced healthcare costs highlights the value created by Delfina Care.
Dr. Fatimah Lalani, Chief Medical Officer at HOPE Clinic in Houston, Texas, shares how Delfina’s AI-powered interventions have improved maternal health. “Since we transformed our practice with Delfina Care, we have seen the positive impact on our pregnant patients’ care daily. We see many patients whose cardiovascular and metabolic challenges we can now proactively manage thanks to Delfina’s insights. Our clinicians have been empowered by Delfina’s system to efficiently provide a new level of proactive care for healthy pregnancy outcomes.”
A Vision for National Scaling and Innovation
The $17 million raised in Delfina’s Series A round will propel our company into our next chapter of growth and innovation. This funding will accelerate our ability to serve more patients nationwide while enhancing our industry-leading predictive technology and interventional support. With our concerted focus on improving maternal health outcomes for all, including in underserved communities, Delfina will serve as a leading technology partner for payors, providers, and families nationwide.
Dr. Senan Ebrahim, Delfina’s founder and CEO, reflects on this funding milestone and its significance for maternal health equity. “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis,” Dr. Ebrahim emphasizes. “We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
Investor Confidence in Life-Changing Innovation
Our Series A is a testament to investor enthusiasm about Delfina’s unique ability to disrupt maternal healthcare for the better. USVP led the round. Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved,” said Dafina Toncheva, USVP General Partner. “We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.
New investors include ARTIS Ventures, Mayo Clinic, and Tokio Marine Future Fund. Additional support came from our existing investors, including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures. Our robust investor ecosystem reinforces the industry’s confidence in Delfina as a leader in solving the maternal health crisis.
Changing the Future of Maternal Care
With this new investment, we are poised to scale the Delfina Care platform and continue delivering on our promise of safer, healthier pregnancies for all. Our focus on improving healthcare outcomes for underserved and underrepresented communities continues, ensuring that no patient is left behind. This is a landmark moment for Delfina and maternal health as a whole—a step toward equity, innovation, and measurable transformation.
The message is clear. Delfina is reimagining how we approach maternal health through technology-driven interventions, compassionate care, and a commitment to reducing disparities. To learn more about our mission and impact, send us a note at partner@delfina.com.
January 28, 2025
The maternal health crisis in the United States is alarming, demanding innovation, determination, and a commitment to equitable care solutions. Delfina has stepped up to this challenge with its mission to transform maternal health outcomes with AI-powered care. Today, we proudly announce our $17 million Series A, led by US Venture Partners (USVP). This milestone represents a pivotal moment in our mission to create a safer, healthier future for expecting parents and their babies.
A Critical Approach to Systemic Challenges in Maternal Health
With a maternal mortality rate more than twice as high as other high-income countries, the U.S. faces a worsening crisis. Black women face disproportionately higher risks, with maternal mortality nearly triple the rate of white women and preterm birth rates 1.4 times higher. Addressing these grave disparities requires a focused commitment and actionable solutions that prioritize equitable access to quality care and address unmet social determinants of health.
Delfina’s AI-powered maternal health platform has already had a measurable impact in these areas. By combining cutting-edge predictive analytics, individualized care interventions, and seamless integration with primary prenatal care teams, Delfina is setting the new standard for proactive, virtual, and data-driven maternal healthcare.
Proven Success with Evidence-Based Care
Healthcare providers who have adopted Delfina are seeing the results firsthand. Our partners – and our data – report marked reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes—key drivers of maternal and infant mortality. Based on these improved health outcomes, Delfina guarantees threefold same-year cost savings for health plans. The combination of healthier pregnancies and reduced healthcare costs highlights the value created by Delfina Care.
Dr. Fatimah Lalani, Chief Medical Officer at HOPE Clinic in Houston, Texas, shares how Delfina’s AI-powered interventions have improved maternal health. “Since we transformed our practice with Delfina Care, we have seen the positive impact on our pregnant patients’ care daily. We see many patients whose cardiovascular and metabolic challenges we can now proactively manage thanks to Delfina’s insights. Our clinicians have been empowered by Delfina’s system to efficiently provide a new level of proactive care for healthy pregnancy outcomes.”
A Vision for National Scaling and Innovation
The $17 million raised in Delfina’s Series A round will propel our company into our next chapter of growth and innovation. This funding will accelerate our ability to serve more patients nationwide while enhancing our industry-leading predictive technology and interventional support. With our concerted focus on improving maternal health outcomes for all, including in underserved communities, Delfina will serve as a leading technology partner for payors, providers, and families nationwide.
Dr. Senan Ebrahim, Delfina’s founder and CEO, reflects on this funding milestone and its significance for maternal health equity. “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis,” Dr. Ebrahim emphasizes. “We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
Investor Confidence in Life-Changing Innovation
Our Series A is a testament to investor enthusiasm about Delfina’s unique ability to disrupt maternal healthcare for the better. USVP led the round. Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved,” said Dafina Toncheva, USVP General Partner. “We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.
New investors include ARTIS Ventures, Mayo Clinic, and Tokio Marine Future Fund. Additional support came from our existing investors, including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures. Our robust investor ecosystem reinforces the industry’s confidence in Delfina as a leader in solving the maternal health crisis.
Changing the Future of Maternal Care
With this new investment, we are poised to scale the Delfina Care platform and continue delivering on our promise of safer, healthier pregnancies for all. Our focus on improving healthcare outcomes for underserved and underrepresented communities continues, ensuring that no patient is left behind. This is a landmark moment for Delfina and maternal health as a whole—a step toward equity, innovation, and measurable transformation.
The message is clear. Delfina is reimagining how we approach maternal health through technology-driven interventions, compassionate care, and a commitment to reducing disparities. To learn more about our mission and impact, send us a note at partner@delfina.com.
January 28, 2025
The maternal health crisis in the United States is alarming, demanding innovation, determination, and a commitment to equitable care solutions. Delfina has stepped up to this challenge with its mission to transform maternal health outcomes with AI-powered care. Today, we proudly announce our $17 million Series A, led by US Venture Partners (USVP). This milestone represents a pivotal moment in our mission to create a safer, healthier future for expecting parents and their babies.
A Critical Approach to Systemic Challenges in Maternal Health
With a maternal mortality rate more than twice as high as other high-income countries, the U.S. faces a worsening crisis. Black women face disproportionately higher risks, with maternal mortality nearly triple the rate of white women and preterm birth rates 1.4 times higher. Addressing these grave disparities requires a focused commitment and actionable solutions that prioritize equitable access to quality care and address unmet social determinants of health.
Delfina’s AI-powered maternal health platform has already had a measurable impact in these areas. By combining cutting-edge predictive analytics, individualized care interventions, and seamless integration with primary prenatal care teams, Delfina is setting the new standard for proactive, virtual, and data-driven maternal healthcare.
Proven Success with Evidence-Based Care
Healthcare providers who have adopted Delfina are seeing the results firsthand. Our partners – and our data – report marked reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes—key drivers of maternal and infant mortality. Based on these improved health outcomes, Delfina guarantees threefold same-year cost savings for health plans. The combination of healthier pregnancies and reduced healthcare costs highlights the value created by Delfina Care.
Dr. Fatimah Lalani, Chief Medical Officer at HOPE Clinic in Houston, Texas, shares how Delfina’s AI-powered interventions have improved maternal health. “Since we transformed our practice with Delfina Care, we have seen the positive impact on our pregnant patients’ care daily. We see many patients whose cardiovascular and metabolic challenges we can now proactively manage thanks to Delfina’s insights. Our clinicians have been empowered by Delfina’s system to efficiently provide a new level of proactive care for healthy pregnancy outcomes.”
A Vision for National Scaling and Innovation
The $17 million raised in Delfina’s Series A round will propel our company into our next chapter of growth and innovation. This funding will accelerate our ability to serve more patients nationwide while enhancing our industry-leading predictive technology and interventional support. With our concerted focus on improving maternal health outcomes for all, including in underserved communities, Delfina will serve as a leading technology partner for payors, providers, and families nationwide.
Dr. Senan Ebrahim, Delfina’s founder and CEO, reflects on this funding milestone and its significance for maternal health equity. “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis,” Dr. Ebrahim emphasizes. “We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
Investor Confidence in Life-Changing Innovation
Our Series A is a testament to investor enthusiasm about Delfina’s unique ability to disrupt maternal healthcare for the better. USVP led the round. Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved,” said Dafina Toncheva, USVP General Partner. “We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.
New investors include ARTIS Ventures, Mayo Clinic, and Tokio Marine Future Fund. Additional support came from our existing investors, including Story Ventures, SemperVirens, Bread and Butter Ventures, Boutique Ventures, and Chelsea Clinton’s Metrodora Ventures. Our robust investor ecosystem reinforces the industry’s confidence in Delfina as a leader in solving the maternal health crisis.
Changing the Future of Maternal Care
With this new investment, we are poised to scale the Delfina Care platform and continue delivering on our promise of safer, healthier pregnancies for all. Our focus on improving healthcare outcomes for underserved and underrepresented communities continues, ensuring that no patient is left behind. This is a landmark moment for Delfina and maternal health as a whole—a step toward equity, innovation, and measurable transformation.
The message is clear. Delfina is reimagining how we approach maternal health through technology-driven interventions, compassionate care, and a commitment to reducing disparities. To learn more about our mission and impact, send us a note at partner@delfina.com.
January 28, 2025
